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ABSTRACT

Watkins, Lauren E. M.S.B.M.E., Purdue University, May 2016. Densified Collagen-Fibril
Biomaterials for Bone Tissue Engineering. Major Professor: Sherry Voytik-Harbin.

Millions of craniofacial bone defects occur annually as a result of trauma,
congenital defects, disease, or tooth extraction1, 2. When present in the oral cavity,
these defects are associated with adverse impacts on speech, mastication, and
aesthetics3, 4. Thus, there is a clinical need for interventional strategies to restore and
preserve alveolar bone mass to improve the success of future treatment options
intended to reestablish functionality and aesthetics. Guided bone regeneration using
bone grafts and a membrane represent the current standard of care for repairing
alveolar bone defects, but face a number of limitations related to resorption time and
structural integrity. Improvements may be directed toward the development of bone
graft substitutes that are patient-specific, provide structural support to the defect, and
promote rapid bone regeneration. Here, we describe the design of a densified, oligomer
collagen-fibril bone regeneration template inspired by the natural progression of bone
defect healing. As the dominant component of the bone organic matrix and the soft
callus formed first during bone fracture healing, type I collagen provides a
physiologically-relevant material for promoting bone regeneration. The polymerizable
oligomer collagen formulation preserves fibrillar and suprafibrillar microstructures
necessary for directing mineral deposition and also facilitates cellular encapsulation
with minimal shape distortion. The densified oligomer collagen-fibril materials promote
accelerated and enhanced mineralization by encapsulated human adipose-derived stem
cells in vitro when compared to conventional collagen-based bone regeneration
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strategies. This works supports the continued development of oligomer collagen-fibril
bone regeneration templates to restore and preserve alveolar bone mass in vivo.

1

CHAPTER 1.

1.1

INTRODUCTION

A Clinical Need Exists to Preserve and Restore Bone Mass in Alveolar Defects

Craniofacial bone defects impact a large portion of the western population. Millions of
individuals experience craniofacial bone defects attributable to trauma, congenital
abnormalities, cancer treatment, or other diseases1, 2. Additionally, the World Health
Organization estimates that 240 million people are missing at least one tooth 3.
Approximately 70% of tooth loss is attributable to periodontal disease, a severe
bacterial infection of the oral tissues3. If left untreated, periodontal disease leads to
gingival and bone recession and eventually tooth loss. Tooth extraction is also
performed on over 10 million individuals in the U.S.A. annually due to trauma, dental
caries, or abscesses3. Bone defects in the oral cavity can negatively impact speech,
mastication, and aesthetics and can also lead to bone resorption around adjacent teeth 3,
4.

Clinical interventions such as dental implants strive to restore function and
aesthetics. Dental implants enable recovery of 85% of the original mastication abilities
and mitigate the speech and aesthetic complications associated with tooth loss 3. The
continuous application of pressure on the alveolar ridge prevents further bone
resorption3. Implants have over a 96% success rate provided successful bone
remodeling occurs to anchor the implant into the host bone3. Implant retention and
aesthetics are dependent on the quantity and quality of bone available at the defect site.
In the absence of clinical intervention, defects in the alveolar ridge of the jaw heal but
can involve significant bone loss that compromises the success of future treatment
options. There is a clinical need for interventional strategies to restore and preserve
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bone mass in order to improve the success of implants intended to reestablish
functionality and aesthetics3, 7-9.

1.2

Alveolar Bone Exhibits Hierarchical Structures and Follows Normal Mechanisms
of Bone Repair
1.2.1 Hierarchical Structure of Bone

Similar to skeletal bone tissue, craniofacial bone tissue is a highly ordered composite of
hydroxyapatite mineral (Ca10(PO4)6(OH)2) and an organic matrix, of which 90% is type I
collagen21, 23. During bone development and regeneration, osteoblasts produce a highly
collagenous matrix that mediates apatite mineral deposition19. Type I collagen
molecules are composed of three α-helical chains that supercoil to form a triple helix
with telopeptide regions on either end19. Side chains on each helix and on the
telopeptide ends are accessible for binding interactions, contributing to the formation of
intermolecular crosslinks between collagen molecules and supramolecular assembly
into highly integrated collagen-fibril matrices19, 24. The type I collagen found in bone
tissue features pyridinoline and pyrrole crosslinks at the termini of each triple-helix
molecule23, 25. These intermolecular crosslinks enable collagen molecule self-assembly
into two-dimensional quarter-staggered arrays with regularly distributed holes and
overlap zones, which further pack and assemble to create channels. It is within these
intermolecular spaces that apatite crystal nucleation and growth occur.
Apatite crystal formation begins within the hole zones of crosslinked collagen
molecule networks. These collagen molecules, and their higher-order three-dimensional
arrangement places negatively charged amino acid residues in close proximity,
particularly within the hole or overlap zones26. Osteoblast-secreted matrix vesicles act
to increase local saturation of calcium and phosphate ions within the collagen matrix 19.
Within these vesicles, three calcium ions and one phosphate ion19 form clusters that
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associate with hydroxyl and carbonyl groups on the collagen strand27. In particular, the
stereochemical arrangement of carboxylate residues at the telopeptide ends bind
calcium ions with high affinity26, 27. Strong collagen-ion binding interactions guide the
preferential orientation of apatite crystals along the crystallographic c-axis and dictate
the characteristic platelet shape of apatite crystals19, 27. The apatite grows
independently to fill the regions between the collagen gaps. The mineralized collagen
matrix is remodeled over time to produce oriented fibrils and the characteristic lamellar
structure of bone.

1.2.2 Natural Mechanisms of Alveolar Defect Repair
Alveolar bone defects heal via normal mechanisms of bone repair (Figure 1A).
Immediately after tooth extraction or loss, an inflammatory response occurs that
recruits a host of signaling molecules and cells to the defect site5. Mesenchymal stem
cells, osteoblast precursors, and endothelial cells migrate to the injured tissue during
the first few days after injury. During the first two weeks, vascularization of the defect
site occurs to supply nutrients to the wound bed. Additionally, migratory cells
differentiate into osteoblasts and deposit a collagenous matrix called the osteoid that
provides a template for mineral formation6. The osteoid is mineralized over the next
four weeks. The new bone tissue is gradually remodeled during the subsequent months
to generate a more organized, mature structure. However, the absence of mechanical
loading at the wound site results in the loss of up to 3 mm (30%) in height and 5 mm
(50%) in width during the first year following tooth loss7.
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1.3

A Gap Exists in the Current Standard of Care, Indicating a Remaining Clinical
Need for Improved Bone Regeneration Strategies

Clinicians are increasingly utilizing bone regeneration strategies to preserve bone mass
and to prepare defect sites for future treatment options such as implants. Guided bone
regeneration (GBR) using a combination of bone grafts and membranes represents the
standard of care for alveolar defects3, 7, 10. Bone grafts derived from processed cadaver
or bovine bone stimulate production of vital bone7. Grafts prepared from donor bone
are osteoinductive (recruits stem cells and induces differentiation) and osteoconductive
(material properties promote cell growth and bone formation), but not osteogenic (do
not contain cells that produce bone)1, 11. These bone grafts are packed into the defect
site then often sealed with a membrane, which stabilizes the graft and acts as a barrier
to prevent infection and soft tissue invasion7, 10 (Figure 1B). Some membranes (e.g.
collagen and some synthetic polymers) are resorbed but others (e.g. high-density
polytetrafluoroethylene) must be removed at a later date3, 10. This type of therapy may
be used before, or at the same time as, implant placement. In a staged approach, the
bone graft is left to stabilize and remodel for 3-6 months before implants are placed7.
Alternatively, GBR and implant may be placed simultaneously to help expedite the
healing process7. In these cases, bone grafts are placed to facilitate osteointegration if
voids between the implant and alveolus measure 2 mm or greater7.
The materials used for bone grafts and membranes have been met with
considerable success but have a number of limitations. The bone grafts are supplied in a
particulate or putty format, which lack shape retention and structural support to
maintain the defect site dimensions7. Additionally, cell-mediated resorption of the grafts
is slow; replacement with vital bone occurs 6-12 months after implantation7. Each of the
materials used to fabricate membranes is associated with specific benefits and
limitations7, 10. Nonresorbable membranes fabricated from materials such as highdensity polytetrafluoroethylene promote bone regeneration by protecting the wound
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bed and providing sufficient mechanical strength to support compressive loading 10.
However, these membranes require surgical removal and increase the cost and pain
associated with treatment7. Membranes composed from synthetic polymers or collagen
resorb over time. Synthetic polymer-based membranes may be tuned to exhibit high
initial structural support12 but the materials rapidly degrade in vivo and the mechanical
strength is rapidly lost10, 13. These materials may be fabricated to mimic the nanofiber
structure of the extracellular matrix but generally have less favorable cell interactions in
comparison to natural polymers such as collagen12, 14. Collagen-based membranes are
biocompatible and promote cellular attachment and proliferation15. Conventionally,
these materials are prepared from a slurry of undissociated, fibrillar type I collagen and
may be used in combination with growth factors or antibiotics7, 14. However, these
membranes have low mechanical properties and unpredictable degradation profiles 10
which can present challenges with space maintenance of alveolar defects14, 16.
Exogenous crosslinking, by chemical or physical means, offers more control over the
mechanical properties of the membranes but can negatively impact the cellular
interactions10, 17, 18. Composite collagen/nano-hydroxyapatite scaffolds prepared by
direct mixing of synthetic nano-hydroxyapatite and insoluble collagen19 have been
investigated as another method of increasing the mechanical integrity of collagen
materials15 but were found to exhibit weak binding, leading to unpredictable
degradation rates and mechanical properties19. Furthermore, the hydroxyapatite
crystals have no structural similarity to native bone and remain unaltered long after
implantation, hindering bone formation and remodeling19. After reviewing the clinical
performance of bone grafts and membranes, the National Institute of Dental and
Craniofacial Research (NIDCR) indicated that there is still a clinical need for “patientspecific therapies to repair bone and supporting structures around the teeth and for
long-lasting bone support of tooth replacement dental implants”9.
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Figure 1: (A) The normal healing sequence for alveolar defects involves extensive bone
resorption 1 year after tooth loss. (B) Allografts or xenografts in the form of
(de)mineralized chips or putty are packed into the defect site and covered with a
membrane. Bone grafting preserves bone mass of the alveolar ridge.

1.4

Design Requirements Focus on Replicating Bone Regeneration

After analyzing the gaps in the current standards of care, three criteria for the design of
improved bone regeneration therapies intended for alveolar defects were developed:
patient-specific, physical support for the defect site and implant, and rapid generation
of high-quality bone tissue. Firstly, the bone graft substitute should be patient-specific9
in that it may be customized to the dimensions of the bone defect and may be prepared
to include autologous cells or other components (e.g. antibiotics, growth factors)
appropriate for the specific case. Secondly, the bone graft substitute should provide
physical support to the defect site and to the implant9, 11. The material should exhibit
adequate shape retention and mechanical integrity to support compressive loading and
maintain the defect site dimensions. Finally, it should rapidly promote the development
of high-quality, healthy bone tissue that allows for replacement by and integration with
host tissues over time9, 10, 19. Most engineered bone graft substitutes aim to replace the
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final form and function of mature bone12, 19 but recent trends have emerged shifting
focus towards regenerative biology13, 20. Ideally, bone graft substitutes should focus on
replicating the rapid process of natural bone regeneration and enabling integration with
surrounding tissue13, 20. As the dominant component of the bone organic matrix21 and
the soft callus formed as the template in bone defect healing, type I collagen may
provide an ideal physical and chemical material for bone graft substitutes 22. Its excellent
biocompatibility and cellular interactions encourage host tissue invasion and
remodeling14. Engineered tissue constructs composed purely of type I collagen might
reproduce the natural progression of bone development.

1.5

Proposed Solution: A Type I Collagen-Based Bone Regeneration Template

Polymerizable, soluble collagen formulations facilitate the development of collagenbased materials that are patient-specific. Alveolar defects vary in size and shape, and
patient lifestyles or health can impact clinical outcomes associated with bone
regeneration strategies10. Polymerizable collagen formulations are inherently versatile.
The polymerizable solutions support injection and polymerization in vivo or can be
prepared in a mold customized to the specific defect dimensions. This format also
facilitates the incorporation of cells, growth factors, or other bioactive molecules. Bone
graft substitutes that contain cells at the time of placement have the potential to
generate faster and more reliable bone regeneration when compared to acellular
materials13, 28. Furthermore, polymerizable collagen has been demonstrated to enhance
cell-matrix interactions15 to promote adhesion, proliferation, and stem cell
differentiation29, 30. Conventional polymerizable collagen formulations represent
atelocollagen and telocollagen formulations. Atelocollagen molecules, which are
isolated by acid extraction in the presence of pepsin, lack telopeptide regions that are
critical for molecular alignment, intermolecular crosslinking, and mineral formation 19, 31.
Telocollagen formulations retain the telopeptide region but, unable to induce
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supramolecular assembly and interfibril associations, yield matrices consisting of
entanglements of long individual fibrils. In contrast, oligomeric collagen is an uncommon
soluble formulation that retains the intramolecular crosslinks found in naturallyoccurring collagen29, 30. Oligomers exhibit rapid fibril and suprafibrillar assembly
generating highly interconnected collagen-fibril matrices32. Recently, techniques were
created for the densification of polymerized collagen-fibril matrices33, 34. Densified tissue
constructs prepared from oligomer collagen-fibril matrices more closely replicate the
multi-structural features, fibril densities, and mechanical properties of soft tissues found
in vivo such as the osteoid34. Fabrication of these dense materials support cellular
encapsulation with cell viability greater than 97%34. Bone regeneration strategies
prepared from type I collagen that preserves fibrillar and suprafibrillar microstructures
could promote the natural development of integrated collagen/hydroxyapatite tissues.
Here, we describe the design of an a polymerizable oligomer collagen-fibril bone
regeneration template to recreate the unmineralized osteoid and address the clinical
need for improved bone graft substitutes (Figure 2). The polymerizable collagen
inherently facilitates dimensional modification for patient-specificity. The work here
investigates parameters for preparing collagen matrices that facilitate cellular
encapsulation without significant shape distortion. Human adipose-derived stem cells
(hASC) were selected as a potential therapeutic source of autologous stem cells with
established success in craniofacial applications35. The structural properties of the
densified tissue constructs were determined to assess their capacity to mechanically
support the alveolar bone defect and the implant. Finally, specific parameters of cell
density and in vitro osteogenic conditions were optimized to determine the capacity of
the collagen template to rapidly promote mineralization. The in vitro model was used to
predict the bone regeneration capacity of the template in vivo.
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Figure 2: The ideal strategy meets three design criteria for the regeneration of alveolar
bone. The proposed solution acts as a template to replicate the natural progression of
bone regeneration.
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CHAPTER 2.

2.1

MATERIALS AND METHODS

Preparation of Collagen-Fibril Constructs

Type I collagen oligomers were acid-solubilized from dermis of market weight pigs, as
described previously30. Pulverized dermis was extracted with sodium acetate to remove
soluble non-collagenous proteins and polysaccharides prior to sodium citrate extraction
of collagen oligomers. Lyophilized oligomer was dissolved in 0.01 N hydrochloric acid
(HCl) and rendered aseptic by chloroform exposure at 4 °C. Oligomer concentration was
determined using a Sirius Red (Direct Red 80) assay36. The oligomer formulation was
standardized based upon molecular composition as well as polymerization capacity
according to ASTM standard F3089-1432. Here, polymerization capacity is defined by
matrix shear storage modulus (G′) as a function of oligomer concentration of the
polymerization reaction. Commercial acid-soluble rat tail collagen (telocollagen) and
pepsin-solubilized bovine dermis collagen (atelocollagen) were obtained from Corning
(Corning, NY) and Advanced BioMatrix (Carlsbad, CA), respectively. All collagen solutions
were diluted with 0.01 N HCl to achieve desired concentrations and neutralized with 10×
phosphate buffered saline (PBS) and 0.1 N sodium hydroxide (NaOH) to achieve pH 7.437.
Neutralized solutions were kept on ice prior to cell encapsulation and/or polymerization.

2.2

Cell Culture

Human adipose-derived stem cells (hASC) were chosen as a potential source of
autologous cells with improved ease of use and availability compared to bone marrowderived stem cells38 that are also capable of robust osteogenic differentiation both in
vitro and in vivo35. Low-passage human adipose-derived stem cells (hASC) were cultured
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as described previously34. Cells were obtained from Zen-Bio (Research Triangle Park, NC)
and cultured in growth medium consisting of Dulbecco's Modified Eagle Medium
(DMEM; Life Technologies, Carlsbad, CA), 10% fetal bovine serum (FBS), 100 U/mL
penicillin, and 100 U/mL streptomyosin (Invitrogen, Grand Island, NY). The hASC were
grown and maintained in a humidified environment of 5% carbon dioxide in air at 37°C.
Cells were kept below 80% confluence and used in experiments at passage 6 to 9.

2.3

Preparation of Cellularized Collagen-Fibril Constructs

Cell-encapsulated collagen-fibril tissue constructs were prepared by suspending hASC in
neutralized collagen solutions. For studies comparing polymerizable collagen
formulations, collagen solutions were prepared at 3.0 mg/mL (atelocollgen) to 3.5
mg/mL (telocollagen and oligomer) and cells were added at a density of 7.5 × 105
cells/mL. Collagen-cell solutions were aliquoted into individual wells of a 96 well plate
(150 µL/well) before polymerization for 15 minutes by warming to 37 °C. Tissue
constructs were cultured with 200 µL osteogenic medium (growth medium
supplemented with 0.05 mM L-ascorbic acid, 10 mM β-glycerophosphate, and 100 nM
dexamethasone) for 7-14 days as specified to induce osteogenic differentiation of hASC.
Medium was changed daily to accommodate the quantity of cells within each matrix.
Recent work by Blum et al defined methods for the densification of acellular and
cellular oligomer collagen-fibril matrices to generate tissue constructs with fibril
densities and mechanical properties similar to soft tissues found in the body34. First, cellencapsulated oligomer collagen-fibril matrices were prepared by aliquoting collagenhASC suspensions into a 96 well plate (150-342 µL/well) and polymerizing for 15
minutes by warming to 37 °C. In a high-throughput modification to the method outlined
by Blum et al, the cellularized matrices were subjected to confined compression using a
96-well ABS 3D-printed platen (6 mm diameter) at a rate of 6 mm/min to yield densified
oligomer collagen-fibril tissue constructs. Post-compression hASC densities were 3 × 106,
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1.5 × 106, or 3 × 107 cells/mL and post-compression collagen-fibril densities were 15, 30,
or 50 mg/mL as specified. Acellular 50 mg/mL constructs for compressive testing were
prepared similarly but in the absence of cells. Immediately following densification,
tissue constructs were transferred to a 48 well plate and 1 mL of medium was added to
each well. Three types of medium were used: growth medium, osteogenic medium, and
calcium-supplemented osteogenic medium. Growth medium was used to have an
unbiased study of the osteoinductivity of the dense collagen-fibril tissue constructs.
Osteogenic medium was used to induce osteogenic differentiation of hASC by providing
soluble factors (dexamethasone, ascorbic acid, and β-glycerophosphate) either in
combination (standard formulation) or individually. Finally, calcium-supplemented
osteogenic medium, consisting of standard osteogenic medium supplemented with 8
mM calcium chloride39, was used to provide an additional source of calcium ions
required for mineral formation. Medium was changed daily to accommodate the
quantity of cells within each tissue construct. Given the design criteria of inducing rapid
mineralization, tissue constructs were cultured for a period of 7 days.

2.4

Assessment of Cell-induced Contraction

Cell-induced contraction of the tissue constructs was determined by measuring the
reduction in surface area of the cylindrical tissue construct40. Photographs were taken of
each construct at specified days throughout the experiment and were analyzed using
ImageJ software made available by the National Institutes of Health. The images were
used to calculate surface area at the given time point. The calculated surface area was
normalized to the surface area of an acellular control group measured immediately
following polymerization. All experimental groups were performed in triplicate.
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2.5

Histological and Structural Analyses of Tissue Constructs

For histological characterization, tissue constructs were fixed using 3%
paraformaldehyde in PBS after 7 days of culture, set in a cryo-embedding compound,
and frozen for sectioning at 20 µm using a cryostat (Sandon Cryotome FE, Thermo
Scientific, Waltham, MA). Alizarin Red S (Sigma Aldrich, St. Louis, MO) stain was used to
detect calcium within the tissue constructs, a marker of osteogenesis and matrix
mineralization39. Sectioned slides were stained with a 2% Alizarin Red S solution (pH 4.2)
for 2 minutes then rinsed four times with deionized water to remove any unbound stain.
Calcium-containing mineralized nodules were stained red and were observed
qualitatively. Five to six stained sections per group were observed with a Nikon Eclipse
E2000 microscope (Nikon Instruments, Melville, NY) equipped with a Leica DFC Digital
Camera (Leica Mircosystems, Wetzlar, Germany). Images were taken at both the center
and edges of each stained section to observe the spatial and size distribution of
mineralized regions.
The microstructure and ultrastructure of collagen-fibril constructs were
characterized through scanning electron microscopy (SEM). SEM specimens were fixed
in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, post-fixed in 1% osmium
tetroxide, dehydrated in a graded ethanol series, and critical point dried in a Tousimis
931 machine. Dried specimens were coated with platinum in a Cressington 208HR
sputter coater. One representative sample per group was imaged at several random
locations using an FEI NOVA nanoSEM 200 field emission scanning electron microscope
(FEI Company, Hillsboro Oregon) using an ET (Everhart-Thornley) detector or the highresolution through-the lens (TLD) detector operating at an accelerating voltage of 5kV,
spot 3, ~5.0 mm working distance, and 30m aperture. Qualitative observations on
porosity and collagen-fibril associations were noted.
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2.6

Compositional Analysis of Mineralized Tissue Constructs

Analysis of the chemical composition of minerals within the samples was performed by
coupling energy-dispersive x-ray spectroscopy (EDX) with SEM. Samples were imaged
with an FEI Quanta 3D FEG scanning electron microscope (FEI Company, Hillsboro, OR)
using the Everhart-Thornley (ET) detector at high vacuum. Parameters for imaging were
5kV, spot 5, 50µm aperture, and working distance of ~10 mm. EDX was done with an
Oxford INCA Xstream-2 with Xmax80 detector (Oxford Instruments, Peabody, MA) with
the analytical mode at 10kV, spot 1, 1000µm objective aperture, and a P4 System. The
“Point and ID” method was used to analyze the atomic composition of three
representative mineralized regions per culture condition. For each area, spectral peaks
were used to identify and quantify the specific atoms present within the mineral by
atomic percent. Raw atomic percent of calcium and phosphate, as well as the calcium to
phosphate ratio (calculated as the ratio of atomic percent calcium to atomic percent
phosphate), are displayed as the average ± standard deviation along with a
representative spectrum.
MicroCT analysis was performed with a microCT 40 instrument (SANCO Medical
AG, Switzerland) at 45 kV and 188 µA and a spatial resolution of 6 µm to determine the
distribution of mineral within the samples after 1 week of culture 40. The analysis was
conducted with a low gray threshold setting of 170 and upper gray threshold of 1000 to
remove background signal. A 3D reconstruction of the sample was created to observe
the distribution of dense, mineralized regions throughout the tissue construct. A
volumetric analysis function was used to calculate the volume fraction of mineralized
collagen, expressed as the ratio of mineralized volume to total volume (MV/TV, %).
Three scans were performed per experimental group.
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2.7

Mechanical Testing of Tissue Constructs

Constructs were tested in unconfined compression at 17%/second to 80% strain using a
servoelectric materials testing system (Bose, Eden Prairie, MN) adapted with a 40 N load
cell34. Engineering stress and strain were calculated assuming the tissue constructs
represent homogenous materials with constant cross-sectional area. Compressive
modulus was calculated as the slope of the linear region of the stress-strain curve.
Compression tests were performed on four independent constructs per group.

2.8

Statistical Analysis

Statistical analysis was performed using Minitab statistical software. Cell-induced
contraction between collagen formulations was compared using a two-way ANOVA with
a Tukey post-hoc test; all other comparisons of contraction and mechanical properties
between construct groups were made by applying a one-way ANOVA with a Tukey posthoc test to determine differences in mean values. Calcium-phosphate ratios were
compared using a two-sample student’s t test. A critical global p-value of 0.05 was used.

.
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CHAPTER 3.

3.1

RESULTS AND DISCUSSION

Self-Assembling Oligomer, but not Conventional Collagen Formulations, Possess
the Necessary Mechanical Integrity and Microstructure to Support Cellular
Encapsulation and Mineralization

Pre-formed collagen materials currently utilized as membranes rely upon cellular
migration and infiltration for mineralization. It has been suggested that materials
containing cells upon the time of placement have the potential to generate faster and
more reliable bone formation13, 28, indicating that polymerizable collagen formulations
amenable to cellular delivery may impact bone regeneration. Our group (T. Smith,
unpublished) and others have observed similar or expedited bone regeneration rates
using alternative, polymerizable collagen formulations amenable to cellular
encapsulation41. Here, we extend this work by comparing the capacity of three collagen
formulations for cellular delivery.
Three collagen formulations, differing in their polymerization capacity, were
utilized to determine an optimal formulation for cellular encapsulation. Here, this was
defined as resistance to cell-induced matrix contraction. Type I collagen-fibril matrices
were prepared from commercially available telocollagen and atelocollagen as well as
laboratory produced oligomer collagen (3.0-3.5 mg/mL). Human adipose-derived stem
cells (hASC) were encapsulated within these matrices at 7.5x105 cells/mL and cultured
under standard osteogenic conditions for 14 days42, 43. Significant cell-induced
contraction was observed for both atelocollagen and telocollagen matrices after 3 days
of culture (p < 0.001) (Figure 3 A & B). Atelocollagen and telocollagen matrices
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continued to exhibit significant cell-induced contraction throughout the duration of the
experiment when compared to the oligomer (p < 0.001). After 14 days, atelocollagen
and telocollagen matrices had contracted by 92.6 ± 3.3% and 86.1 ± 0.4%, whereas
oligomer matrices contracted by 4.8 ± 6.5%.
These results are consistent with previous work describing the importance of
telopeptide regions and intermolecular crosslinks on supramolecular assembly capacity
of type I collagen formulations29. As described earlier, atelocollagen molecules lack the
telopeptide regions critical for molecular alignment and intermolecular crosslinking 31.
Telocollagen formulations retain the telopeptide region but, unable to induce
supramolecular assembly and interfibril associations, yield matrices consisting of
entanglements of long individual fibrils. Oligomer collagen formulations retain the
natural intermolecular crosslinks enabling rapid fibril and suprafibrillar assembly of
highly interconnected matrices. In comparison to conventional atelocollagen and
telocollagen formulations, self-assembled oligomer matrices have been found to exhibit
improved mechanical integrity, resistance to proteolytic degradation and cell-induced
contraction, and handling capacity29, 44, 45. The differences in microstructure and
mechanical integrity were observed via cell-mediated matrix contraction. The fibril
microstructure and associated mechanical properties of self-assembled oligomers
resists matrix contraction by encapsulated cells and thus are a suitable polymerizable
collagen formulation for the creation of cellularized tissue constructs.
Scanning electron microscopy (SEM) was used to validate that the oligomer
formulation would support mineralization. SEM micrographs of cellularized oligomer
matrices reveal fibrillar mineralization after 14 days of culture in osteogenic medium
(Figure 3C). As described previously, several studies have outlined the importance of
telopeptide regions and gap zones created by collagen crosslinking on the formation of
apatite crystals19, 26. The oligomer collagen formulation used in this experiment retains
the hydroxylysinonorleucine intermolecular crosslink associated with its dermal origin 44
which differs from the pyridinoline and deoxypyridinoline crosslinks characteristic of
type I collagen found in bone25. Mineral deposition appears to depend more upon the
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presence of a suprafibrillar structure and gap zones between collagen molecules and
less upon the type of crosslink between them, since oligomer collagen supports cellmediated apatite nucleation and crystal growth as occurs in vivo. In comparison, neither
acellular telocollagen matrices nor cellular matrices cultured in osteogenic medium for 2
and 4 weeks, respectively, exhibit fibrillar mineralization and instead display localized
mineral clusters41.

Figure 3: Collagen-fibril matrices of commercial atelocollagen (PureCol) and telocollagen
(BD Rat Tail) and laboratory-produced oligomer collagen formulations were prepared at
fibril densities of 3.0-3.5 mg/mL and encapsulated with 7.5x105 hASCs/mL. Collagen
matrices were cultured in standard osteogenic medium for 14 days. (A) Contraction was
observed as early as day 3 in atelocollagen and telocollagen matrices. (B) Atelocollagen
and telocollagen matrices contracted significantly in comparison to the oligomer
matrices. Letters indicate statistically significant groups (p < 0.05). (C) SEM micrographs
of oligomer matrices reveal fibril-level mineralization.
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3.2

Increasing Collagen-Fibril Density Assists in Dimensional Maintenance with High
Cell Densities but is not Alone Sufficient to Induce Osteogenesis In Vitro

Dimensional maintenance of the alveolar ridge motivates ridge augmentation via bone
graft substitutes. Previous work has shown that increasing oligomer collagen-fibril
density corresponds to increased mechanical properties, improved shape definition, and
resistance to cell-induced contraction29. Furthermore, the application of confined
compression to low-density oligomer collagen fibril matrices yields materials with multiscale structural properties similar to those of the soft tissues found in the body,
including the osteoid34.
Confined compression was used to create cellularized tissue constructs with
increasing fibril densities to examine the effect of collagen-fibril density on scaffold
dimensional maintenance and osteogenic differentiation of encapsulated hASC.
Cellularized tissue constructs were created by applying plastic compression to hASCencapsulated 3.5 mg/mL oligomer matrices to achieve final fibril densities of 3.5, 10, 30,
and 50 mg/mL and a final cell density of 3𝑥106 cells/mL. Increasing collagen-fibril
density significantly reduced the extent of cell-induced contraction (p < 0.001) following
1 week of culture in standard growth medium (Figure 4 A & B). While 3.5 mg/mL
constructs contracted by 93.2 ± 1.4%, the 50 mg/mL constructs contracted by 7.9 ± 3.5%.
Increasing fibril density to 50 mg/mL through confined compression provided the
greatest control over cell-induced contraction and dimensional distortion.
The osteogenic differentiation of encapsulated hASC was assessed using Alizarin
Red, which stains mineralized regions. Calcified nodules are absent at the center of the
tissue constructs and are sparse at the periphery of 15 and 30 mg/mL groups (Figure 4C).
Together, these results suggest that while collagen-fibril density may bias hASC toward
osteogenic differentiation, the dense tissue constructs are not osteoinductive. Soluble
factors, such as those contained in standard osteogenic differentiation medium, may be
necessary to provide components (e.g. calcium and phosphate ions) and encourage
robust mineralization in vitro. These findings are consistent with other work

20
demonstrating that matrix stiffness has an important role in the differentiation of
multipotent stem cells but is unable to orchestrate a strong osteogenic response
without the addition of soluble factors29, 46. Increasing fibril density enables cellular
encapsulation at high cell densities without significant contraction but additional factors
are necessary to induce osteogenesis in vitro.
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Figure 4: Human ASC were encapsulated at 3𝑥106 cells/mL within collagen-fibril
constructs with fibril densities of 3.5, 15, 30, or 50 mg/mL and cultured for 7 days with
growth medium. (A, B) Collagen constructs with high fibril density exhibit greater
resistance to cellular contraction as measured by surface area. (C) Alizarin Red staining
was performed to observe regions of mineralization. Scale bars = 50 µm. Letters indicate
statistically different groups (p < 0.05).
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3.3

Dense, 50 mg/mL Oligomer Constructs Provide a Porous Structure with
Compressive Modulus Similar to Pre-Mineralized Osteoid

The osteoid formed during bone development is a dense, collagenous soft tissue
(compressive modulus 24-40 kPa46) but has a porous structure amenable to host tissue
invasion and remodeling6, 12. Highly porous materials prepared from conventional
collagen formulations are traditionally associated with low mechanical properties 18.
Various modifications such as chemical and physical crosslinking are applied to increase
the mechanical performance of collagen materials but often compromise the
biocompatibility and biological signaling capacity inherent to collagen materials 47.
Densification of collagen scaffolds has been demonstrated as a means of increasing
mechanical properties without additional chemical or physical crosslinking34 and
preserves the multi-scale structural features of oligomer collagen matrices33, 34. To
determine the effect of confined compression on the microstructure and the
compressive properties of dense oligomer collagen-fibril constructs (50 mg/mL), SEM
and mechanical analyses were conducted.
Here the ultrastructure and mechanical properties of 50 mg/mL oligomer
matrices with and without encapsulated hASC (3x106 cells/mL) were determined. As
shown in Figure 5A, SEM micrographs of cellular 50 mg/mL constructs revealed an open,
porous microstructure with interfibril branching. Increasing fibril density brought fibrils
in closer proximity to one another (as compared to 3.5 mg/mL constructs, Figure 3C) but
the collagen fibril ultrastructure was not altered. The collagen fibrils are randomly
oriented and display the characteristic collagen D-banding structure. Scaffolds with
randomly ordered features with nanoscale topography have been demonstrated to
direct cellular adhesion, migration, and osteogenic differentiation 15, 20. The observations
on fibril microstructure and porosity are consistent with previous results examining the
microstructure of 12.25 and 24.5 mg/mL collagen-fibril constructs34.
Mechanical compression was applied to both acellular and cellular high-density
(50 mg/mL) tissue constructs to determine the compressive modulus. Representative
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stress-strain curves for each group, calculated using engineering stress and strain, are
shown in Figure 4B. The stress-strain curves for both groups showed two distinct regions:
an initial toe region of nonlinear stress-strain behavior and a linear region. Stressrelaxation was noted upon cessation of compressive loading. The compressive modulus,
calculated from the linear region of each curve, did not differ significantly upon cellular
encapsulation (p = 0.701) (Figure 5 B & C). Acellular constructs had a compressive
modulus of 31.4±16.0 kPa compared to 26.6±13.4 kPa for tissue constructs
encapsulated with 3𝑥106 hASC/mL. The compressive modulus for acellular densified
oligomer constructs differs from expected results from previous studies with densified
oligomer constructs34, likely due to differences in sample preparation. However, the
compressive moduli for both cellular and acellular constructs are within the range of
compressive moduli reported for the pre-mineralized osteoid. The compressive modulus
for acellular, dense oligomer constructs is similar to what others have found using
similarly prepared telocollagen constructs (23.5 ± 4.97 kPa)40. The ultrastructure and
compressive properties of the dense, 50 mg/mL oligomer collagen-fibril constructs
replicate the physical properties of the unmineralized osteoid found in vivo.

24

Figure 5: Oligomer collagen-fibril matrices (50 mg/mL) were prepared with and without
encapsulated hASC (3𝑥106 cells/mL). (A) SEM micrographs of cellularized constructs
exhibit a porous microstructure that represents a branched fibril network. (B)
Representative stress-strain curves for acellular and cellular constructs demonstrating a
toe and linear region. (C) Compressive moduli for acellular and cellular constructs did
not differ significantly (p > 0.05).

3.4

Increasing hASC Density Within 50 mg/mL Constructs Enhances and Accelerates
Matrix Mineralization

Cell seeding density has been demonstrated to regulate osteoblast cell proliferation and
differentiation as well as cell-matrix interactions in 3D culture systems48. Increasing cell
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densities between 3𝑥106 − 3𝑥107 cells/mL improves osteoblastic differentiation of
both MG-63 osteosarcoma cell lines and MC3T3 osteoblast precursor cell lines
encapsulated within dense telocollagen constructs after 3-4 weeks41, 48. Here, hASC
were encapsulated within 50 mg/mL oligomer constructs at cell densities within this
reported range to determine an optimum cell density for hASC-mediated bone
regeneration.
To evaluate the specific parameters for the rapid induction of mineralization,
tissue constructs were cultured in osteogenic medium for 7 days then stained with
Alizarin Red to observe the extent of mineral formation. As shown in Figure 6A, the
number of small calcified nodules and size of larger calcified regions appeared to
increase in a cell density-dependent fashion, suggesting that a cell density of 3𝑥107
cells/mL is optimal for osteogenic differentiation of hASC. Additionally, cellular
encapsulation at high densities appeared to accelerate mineral formation; the extent of
matrix mineralization observed at 7 days within oligomer tissue constructs is
comparable to what other groups have observed after 21 days using absorbable
collagen sponges seeded with similar quantities of bone marrow-derived mesenchymal
stem cells43. Dense oligomer tissue constructs encapsulated with high cell densities
promote rapid matrix mineralization.
Interestingly, cell-induced contraction was observed during culture with
osteogenic medium across all cell seeding densities (Figure 6B). Whereas tissue
constructs cultured in growth medium contracted by 7.9 ± 3.5%, those cultured in
osteogenic medium contracted by 71.5 ± 3.7% on average with no significant difference
between cell density groups (p = 0.959). These observations are similar to what other
groups have found using high cell seeding densities in dense telocollagen constructs (7080% contraction after 7 days)40. The observed cell-induced contraction may be
attributable to enhanced cellular proliferation and collagen production promoted by the
components of osteogenic differentiation medium. Future work will investigate
methods of reducing cellular contraction for these optimized culture parameters. For
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example, recent studies in our group have shown that embedding cellularized, low fibrildensity oligomer collagen matrices within a surrounding tissue microenvironment
prevents cell-mediated contraction (K. Buno, unpublished). Experiments will examine
how embedding the tissue constructs within low-fibril-density matrices (1.5 mg/mL)
impacts the extent of cell-induced contraction and matrix mineralization.
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A

B

Figure 6: hASC were encapsulated within 50 mg/mL collagen constructs with final cell
densities of 3𝑥106 , 1.5𝑥107 , and 3𝑥107 cells/mL. Constructs were cultured for 7 days
with osteogenic medium. (A) Constructs were stained with Alizarin Red to observe
mineralization. Scale bars = 50 µm. (B) Cell-induced contraction was observed for all
conditions with no significant difference between groups (p > 0.05).

28
3.5

Osteogenic Medium Optimized for Differentiation in 2D Culture Supports
Osteogenic Differentiation of hASC in 3D

A standard osteogenic medium formulation (DMEM growth medium supplemented with
100 nM dexamethasone (Dex), 0.05 mM L-ascorbic acid-2-phosphate (AA), and 10 mM
beta-glycerophosphate (BGP)49) was developed for the osteogenic differentiation of
mesenchymal stem cells in 2D culture systems. This formulation has been applied for
the osteogenic differentiation of hASC in 2D culture50 but not all components may be
necessary for 3D culture systems with a pre-existing interstitial matrix. Each component
of the standard osteogenic medium formulation was added separately to growth
medium to determine the minimum combination of components necessary to create a
strong osteogenic response of hASC in 3D culture.
HASC-encapsulated oligomer tissue constructs (1.5𝑥107 cells/mL, 50 mg/mL)
were cultured for 7 days in growth medium supplemented with (i) Dex, (ii) AA, (iii) BGP,
(iv) AA and BGP, or (v) complete osteogenic medium representing the standard
formulation that contains all three components. Growth medium served as a control
culture condition. Alizarin Red stain for calcified extracellular matrix was used as a
histologic marker of osteogenic differentiation. There was an absence of calcification in
tissue constructs cultured for 7 days in growth medium and growth medium
supplemented with either Dex or AA (Figure 7). Disperse, large mineralized regions were
observed in samples cultured with BGP-supplemented medium. The addition of both AA
and BGP to growth medium increased the number and size distribution of calcified
nodules. Qualitatively, samples cultured in complete osteogenic medium exhibit the
largest calcified regions when compared to other culture conditions and also have
several smaller nodules. These observations suggest that the standard osteogenic
medium formulation produces the greatest osteogenic response of hASC in 3D culture.
These results are consistent with published literature on the mechanism of action of
each osteogenic medium component51. In combination, the osteogenic differentiation
medium components induce cell proliferation and osteoblast differentiation via specific
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gene expression, increase secretion and remodeling of type I collagen, and provide a
source of phosphate ions for mineral formation51. From this study, it appears that
standard osteogenic medium is appropriate for osteogenic differentiation of hASC
within 3D collagen tissue constructs.

Figure 7: Human ASC were seeded in 50 mg/mL collagen constructs with a final cell
density of 1.5𝑥107 cells/mL. Constructs were cultured for 7 days with growth medium
containing dexamethasone (Dex), ascorbic acid (AA), beta-glycerophosphate (BGP), AA +
BGP, or complete osteogenic medium containing all three components. Constructs were
stained with Alizarin Red to observe mineralization. Scale bars = 50 µm.

3.6

Calcium Concentration in Osteogenic Medium Modulates Mineral Distribution
and Quality

The calcium to phosphate ratio of natural hydroxyapatite, as determined by its
molecular structure, is 1.6752. Standard DMEM medium contains 1.8 mM calcium ions
and osteogenic medium provides 10 mM phosphate ions, suggesting a disproportionate
supply of ions critical for apatite formation. Ionic calcium levels of 8 mM in both growth
and osteogenic medium have been shown to increase the quantity and rate of
ossification during in vitro culture39. Tissue constructs were cultured in either the
presence or absence of 8 mM ionic calcium to determine if calcium is a limiting factor
for standard in vitro models of osteogenesis. The osteogenic behavior of hASC was
assessed by examining the resulting matrix and mineral properties.
Tissue constructs (50 mg/mL) encapsulated with hASC at 3𝑥107 cells/mL were
cultured for 7 days in growth medium or osteogenic medium with and without of 8 mM
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calcium chloride as a source of calcium ions. Alizarin Red stain was used to observe
mineral deposition within the tissue constructs (Figure 8). Samples cultured with growth
medium exhibit no calcified nodules. The addition of extracellular calcium to growth
medium results in the presence of both small and medium-sized calcified nodules with a
disperse but homogenous distribution throughout the construct. Samples cultured in
standard osteogenic medium had a high concentration of both large and small calcified
nodules at the periphery of the tissue construct but a low distribution at the core.
Calcium-supplemented osteogenic medium increased the presence of mineralized
matrix. Mineralized regions were surrounded by a general red hue in the matrix and had
softer edges than those found in standard osteogenic conditions. Additionally, the
peripheral effect observed in calcium-supplemented osteogenic medium was less
distinct than what was observed for standard osteogenic medium. Calciumsupplemented tissue constructs had a high distribution of mineralized regions at the
edges of the construct but also throughout the core. These histological observations
suggest that calcium concentration in culture medium modulates mineral distribution
within the scaffold. These results are consistent with studies of calcium and phosphate
ions as chemical signaling factors. Specifically, extracellular ionic calcium is an important
regulator of cellular events in bone regeneration including cell proliferation,
mineralization, and growth factor production in a variety of cell types53-55. Calcium
concentration appears to be a major limiting factor for standard in vitro osteogenic
differentiation conditions.
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Figure 8: Human ASC were encapsulated within 50 mg/mL collagen constructs at a
density of 3𝑥107 cells/mL. Tissue constructs were cultured for 7 days with growth
medium or osteogenic medium, either alone or supplemented with 8 mM calcium.
Alizarin Red was used to stain regions of matrix calcification at the center (top) and
periphery (bottom) of the tissue constructs. Scale bars = 50 µm.

MicroCT was utilized to further analyze the mineral distribution and quantify the
mineralized volume fraction within hASC-encapsulated tissue constructs. Analysis was
conducted at an early time point of 7 days to assess the capacity of the tissue construct
to rapidly induce mineralization. 3D reconstruction of tissue constructs cultured with
standard and calcium-supplemented osteogenic medium are shown in Figure 9A. The 3D
reconstructions for tissue constructs cultured in standard osteogenic medium display
disperse areas of radiographically dense regions throughout the construct with a greater
distribution of dense regions at the periphery. The mineralized matrix observed in
histological sections for these groups may not correspond to mature, dense minerals
that can be observed radiographically. In contrast to the standard osteogenic conditions,
calcium-supplemented groups exhibit dense regions around the periphery but also
throughout the center of the tissue construct. The mineralized volume fraction
(mineralized volume/total volume, %) of tissue constructs cultured in calciumsupplemented osteogenic medium (3.03 ± 0.86%) was significantly greater (p = 0.0037)
than for tissue constructs cultured in standard osteogenic medium (0.007 ± 0.001%)
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(Figure 9B). An acellular construct cultured for 7 days in calcium-supplemented
osteogenic medium had a mineralized volume fraction of 0.41 ± 0.18% (data not shown).
The mineral distribution observed in hASC-seeded dense oligomer tissue constructs
cultured in calcium-supplemented osteogenic medium is comparable at 1 week to what
other groups have found in dense telocollagen constructs encapsulated with mouse
osteoblasts after 4-7 weeks of culture with standard osteogenic medium41. Dense
telocollagen constructs had mineralized volume fractions of 0.05% after incubation in
simulated body fluid for 1 week56 and 0.22% after culture in osteogenic medium for 8
weeks. Simulated body fluid is a medium formulation with ionic composition similar to
what is found in blood plasma in vivo, with 2.5 mM calcium and 1.0 mM phosphate56.
MicroCT confirmed that osteogenic medium supplemented with ionic calcium both
expedites and increases the amount of mineralization observed at the periphery and the
center of the construct when compared to standard osteogenic conditions.
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Figure 9: MicroCT was used to analyze the distribution of mineralized regions within
tissue constructs (50 mg/mL, 3x107 hASC/mL) cultured for 7 days in osteogenic medium
or osteogenic medium supplemented with 8 mM calcium chloride. (A) 3D reconstructed
images for each culture condition show the distribution of radiographically dense,
mineralized regions within tissue constructs. (B) The mineralized volume fraction (%
mineralized volume/total volume) was significant greater in constructs cultured with
both osteogenic medium and 8 mM calcium, indicated by the asterisk (p < 0.05).

SEM was coupled with energy dispersive x-ray spectroscopy (EDX) to analyze the
atomic composition of minerals found within the two groups. Three representative
regions within a randomly-selected tissue construct were analyzed for each culture
condition. The SEM micrographs of the two culture conditions further establish the
increased presence of mineralized collagen resulting from calcium supplementation in
osteogenic medium (Figure 10 A & B). Energy spectra obtained with EDX were used to
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identify and quantify the atomic composition of the minerals found within the tissue
constructs. Representative spectra and a summary table are shown in Figure 10 C & D
and Figure 10E, respectively. Minerals present in samples cultured in standard
osteogenic medium had a calcium to phosphate ratio (Ca:P) of 1.49 ± 0.13, in the range
of values reported for amorphous calcium phosphate52. Amorphous calcium phosphate
is a solid with nanometer-sized particles that convert to crystalline apatite with time52.
This material has a role in matrix vesicle-mediated mineralization and represents an
intermediate mineral phase in the development of mature hydroxyapatite57. Extending
the culture duration may provide sufficient time for the amorphous mineral phase to
mature. Minerals within tissue constructs cultured with calcium-supplemented
osteogenic medium exhibit a Ca:P ratio of 1.69 ± 0.10, close to the 1.67 value
characteristic of hydroxyapatite52. For comparison, telocollagen constructs encapsulated
with mouse osteoblasts had a Ca:P ratio of 1.3 after 8 weeks of culture in osteogenic
medium. Calcium supplementation may act to balance the ratio of ions presented to the
culture system and support the rapid production of mature mineral crystals.
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Figure 10: SEM and EDX were used to visualize collagen fibril mineralization and quantify
atomic composition of mineralized regions within tissue constructs (50 mg/mL, 3x10 7
hASC/mL) cultured for 7 days in osteogenic medium (A, C) or osteogenic medium
supplemented with 8 mM calcium chloride (B, D). (E) The atomic composition (atomic %)
calculated from the spectra, and calcium-to-phosphate ratios, are summarized for all
culture conditions. Values represent the average ± standard deviation calculated from 3
representative areas.

Mechanical analysis was performed on each culture condition to determine the
relationship between matrix mineralization and compressive modulus. Acellular
constructs cultured for 7 days in osteogenic medium supplemented with 8 mM calcium

36
chloride served as a control. As shown in Figure 11, the compressive modulus of tissue
constructs cultured for 7 days in osteogenic medium supplemented with calcium (640.6
± 120.6 kPa) was significantly greater (p = 0.001) than the modulus for those cultured in
osteogenic medium (79.0 ± 15.3 kPa) and in growth medium (24.0 ± 10.0). Acellular
constructs cultured for the same duration in calcium-supplemented osteogenic medium
had a compressive modulus of 31.7 ± 15.9 kPa (data not shown). These differences may
be attributable to the presence of newly-synthesized mineral found in osteogenic
conditions, since extracellular matrix mineralization hardens the tissue23. The
compressive modulus of calcium-supplemented tissue constructs reflects the
differences in distribution, density, and presence of crystalline hydroxyapatite crystals
previously observed with histology, microCT, and EDX.
These results suggest that calcium is a limiting factor for osteogenic culture
systems in vitro, as calcium supplementation increased the distribution, density, and
quality of the mineralized matrix. The ionic concentrations of calcium and phosphate
used in the calcium-supplemented osteogenic medium (8 mM and 10 mM, respectively)
are more evenly balanced than what are found in standard osteogenic medium (1.8 mM
and 10 mM, respectively) but may not accurately represent the ionic concentrations
found in vivo. Circulating blood plasma concentrations of calcium and phosphate are
most closely approximated in vitro with simulated body fluid (SBF) which contains 2.5
mM calcium and 1.0 mM phosphate58. However, SBF does not provide the additional
molecules that would be found in the wound bed of a bone defect (such as steroids or
vitamin C as mimicked in osteogenic medium)6. Additionally, ionic concentrations in a
healing bone defect may be elevated in comparison to normal blood plasma resulting
from hydroxyapatite crystal dissolution induced by the acidity of the wound bed 59, 60.
Future studies will be conducted to determine the rate and extent of mineralization
using osteogenic medium with physiologic concentrations of calcium and phosphate but
in vivo studies will be necessary to evaluate the bone regenerative capacity of the tissue
constructs in a more physiologically-relevant model.
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Figure 11: Mechanical analysis was performed to determine the compressive modulus
of tissue constructs (50 mg/mL, 3x107 cells/mL) after 7 days of culture in growth,
osteogenic, or calcium-supplemented (8 mM) osteogenic medium. (A) Representative
stress-strain curves for each culture condition. (B) Compressive modulus for constructs
cultured in calcium-supplemented osteogenic medium was significantly greater than
those found for growth and standard osteogenic conditions, indicated by the asterisk (p
< 0.05).
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CHAPTER 4.

4.1

CONCLUSIONS

Conclusions

Overall, these results support the utilization of densified, self-assembling collagen-fibril
matrices to meet the ideal design criteria for alveolar bone graft substitutes. The fibril
microstructure and associated mechanical properties of self-assembled oligomers
support cellular encapsulation with improved shape retention compared to
conventional polymerizable collagen formulations. We have demonstrated that the
suprafibrillar assembly of oligomer collagen also promotes the in vitro nucleation and
growth of hydroxyapatite crystals to create integrated collagen-hydroxyapatite
composite tissues with multi-scale structures similar to native bone. Densified oligomer
collagen-fibril constructs with fibril densities of 50 mg/mL were found to have
compressive moduli comparable to the unmineralized osteoid deposited during the
natural bone healing process and could provide physical support to the alveolar bone
defect. This work also validates the osteoconductive capacity of the cellularized tissue
constructs, which may act as a bone regeneration template. Tissue constructs
encapsulated with hASC exhibit rapid matrix mineralization, especially in culture
conditions that supply similar concentrations of both calcium and phosphate ions.
Analysis of the mineralized areas showed calcium and phosphorous with a ratio similar
to that of mature hydroxyapatite in contrast to alternative collagen-based tissue
constructs with minerals more similar to amorphous calcium phosphate, a potential
precursors of hydroxyapatite40, 43. Mineralization within the oligomer tissue constructs
was dispersed throughout the tissue construct after just 7 days of culture. The
distribution and mineralized volume fraction were greater than what others have found
in osteoblast-encapsulated telocollagen tissue constructs after 7-8 weeks40, 41. The in
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vitro studies of cellularized oligomer collagen-fibril templates demonstrate the capacity
of these materials to support the rapid production of mature minerals.
The in vitro studies served as a proof-of-concept for the regenerative capacity of
the template in vivo. This material also supports customization to create patient-specific
templates to meet the NIDCR’s stated clinical need. The polymerizable, self-assembling
oligomer collagen formulation chosen to create these tissue constructs accommodates
customization via several avenues – including geometry, fibril density (and associated
mechanical properties), and type and quantity of encapsulated cells – to rapidly
generate materials specific for a given clinical application. For example, the rapidly selfassembling oligomer solution facilitates injection and polymerization in vivo but it may
also be used to quickly produce matrices with specified dimensions using customized
molds. In summary, this bone regeneration template is customizable for specific
applications and may address a gap in the clinical landscape for alveolar bone grafting
by supporting the rapid generation of high quality bone mineral in vitro.

4.2

Future Studies

Future in vitro studies utilizing these tissue constructs will seek to (i) address
concerns with contraction, (ii) further define their ability promote bone regeneration in
vitro, and (iii) determine their capacity for integration with and remodeling by host
tissue. Firstly, studies will be conducted to address the contraction observed during
culture in osteogenic conditions. Recent work in our lab has shown that embedding
cellularized collagen matrices within a surrounding tissue microenvironment prevents
cell-mediated contraction. Experiments will examine how tethering the tissue constructs
within low fibril-density (1.5 mg/mL) matrices impacts the extent of contraction and
osteogenesis. Additional in vitro studies will investigate the osteoconductive capacity of
the tissue constructs, including determining the genetic markers expressed by hASC and
the effect of cell type on the rate and distribution of matrix mineralization. We will also
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compare the distribution and quality of mineral produced in tissue constructs cultured
in calcium-supplemented osteogenic medium to that produced using osteogenic
medium with physiologic ion concentrations. Conducting in vitro studies on the extent
of matrix remodeling during cell-mediated mineralization will offer an opportunity to
gain further insight into the ability for oligomer collagen-fibril matrices to be integrated
and remodeled by cells. These studies will be conducted using a rapid high performance
liquid chromatography-mass spectrometry method to identify and quantify specific nonreducible (mature) crosslinks found in the tissue constructs.
Finally, we will investigate the regenerative capacity of the tissue constructs in
vivo. Preliminary in vivo studies indicate that low density (3.5 mg/mL) oligomer matrices
with and without encapsulated mesenchymal stem cells readily integrate with
surrounding host bone and promote significant bone regeneration in comparison to
control calvaria defects (T. Smith, unpublished). These results suggest that the densified
tissue constructs may also support integration and enhanced bone regeneration in vivo.
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